A study performed for assessment of baseline serological autoantibody profile in prediction of responders to ICIs included lymphoma cases with other solid tumors and found that PD-1 and PD-L1 IgG2 autoantibodies were highly produced in approximately 20% of lymphoma responders. The gene discussed is PDCD1; the disease is lymphoma.